In general , stimulants improved driving performance in ADHD patients ( either in RCTs conducted in simulators and /or cars ) .
MPH-OROS  improved driving performance compared with MAS-XR , placebo , or no-drug conditions .
Although MPH-OROS and MPH-IR produced similar improvements during the day , MPH-IR lost its efficacy in the evening .
MAS-XR also improved driving performance , but worsened driving performance in the evening .
Studies with ATX report conflicting results .
Improvement was more consistent in teenagers and young adults .
In general , treatment with psychostimulants or ATX in therapeutic dosages had no negative impact on driving performance of ADHD patients .
To conclude , treatment with stimulants in therapeutic doses improves driving performance in ADHD patients , especially teenagers and young adults
Adults with Attention Deficit Hyperactivity Disorder ( ADHD ) , especially teenagers and young adults , show important car driving impairments , including risky driving , accidents , fines and suspension of driver׳s license .
We systematic ally review ed the efficacy of stimulant and non-stimulant drugs on driving performance of ADHD patients .
Methylphenidate significantly improves driving performance of adults with attention-deficit hyperactivity disorder: a randomized crossover trial
Although patients with attention-deficit hyperactivity disorder ( ADHD ) have reported improved driving performance on methylpheni date , limited evidence exists to support an effect of treatment on driving performance and some regions prohibit driving on methylpheni date . A r and omized , crossover trial examining the effects of methylpheni date versus placebo on highway driving in 18 adults with ADHD was carried out . After three days of no treatment , patients received either their usual methylpheni date dose ( mean : 14.7 mg ; range : 10—30 mg ) or placebo and then the opposite treatment after a six to seven days washout period . Patients performed a 100 km driving test during normal traffic , 1.5 h after treatment administration . St and ard deviation of lateral position ( SDLP ) , the weaving of the car , was the primary outcome measure . Secondary outcome measurements included the st and ard deviation of speed and patient reports of driving performance . Driving performance was significantly better in the methylpheni date than in the placebo condition , as reflected by the SDLP difference ( 2.3 cm , 95 % CI = 0.8—3.8 , P = 0.004 ) . Variation in speed was similar on treatment and on placebo ( -0.05 km/h , 95 % CI = -0.4 to 0.2 , P = 0.70 ) . Among adults with ADHD , with a history of a positive clinical response to methylpheni date , methylpheni date significantly improves driving performance
In general , stimulants improved driving performance in ADHD patients ( either in RCTs conducted in simulators and /or cars ) .
MPH-OROS  improved driving performance compared with MAS-XR , placebo , or no-drug conditions .
Although MPH-OROS and MPH-IR produced similar improvements during the day , MPH-IR lost its efficacy in the evening .
MAS-XR also improved driving performance , but worsened driving performance in the evening .
Studies with ATX report conflicting results .
Improvement was more consistent in teenagers and young adults .
In general , treatment with psychostimulants or ATX in therapeutic dosages had no negative impact on driving performance of ADHD patients .
To conclude , treatment with stimulants in therapeutic doses improves driving performance in ADHD patients , especially teenagers and young adults
Adults with Attention Deficit Hyperactivity Disorder ( ADHD ) , especially teenagers and young adults , show important car driving impairments , including risky driving , accidents , fines and suspension of driver׳s license .
We systematic ally review ed the efficacy of stimulant and non-stimulant drugs on driving performance of ADHD patients .